Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28;6(12):3655-3658.
doi: 10.1182/bloodadvances.2022007331.

High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia

Eric Durot  1   2 , Lukshe Kanagaratnam  3   4 , Saurabh Zanwar  5 , Elise Toussaint  6 , Efstathios Kastritis  7 , Shirley D'Sa  8 , Miguel Alcoceba  9 , Cécile Tomowiak  10 , Bénédicte Hivert  11 , Caroline Protin  12 , Jithma P Abeykoon  5 , Josephine M I Vos  13 , Anne-Sophie Michallet  14 , Cyrielle Rodier  1   2 , Jehan Dupuis  15 , Stéphane Leprêtre  16 , Fatiha Merabet  17 , Xavier Roussel  18 , Jean-Marc Zini  19 , Caroline Regny  20 , Aisha Patel  8 , Pierre Morel  21 , Damien Roos-Weil  22 , Steven P Treon  23 , Meletios A Dimopoulos  7 , Ramon Garcia-Sanz  9 , Prashant Kapoor  5 , Jorge J Castillo  23 , Alain Jacques Delmer  1   2
Affiliations

High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia

Eric Durot et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Study flowchart and estimated risk of CNS relapse in transformed WM. (A) Flowchart of inclusion. Patients with transformed WM (254) were analyzed, 235 for CNS involvement at HT and 187 for CNS relapse. (B) Cumulative incidence of CNS relapses. (C) Cumulative incidence of CNS relapse stratified by kidney/adrenal involvement. (D) Cumulative incidence of CNS relapse stratified by the presence of MYD88L265P mutation.
See this image and copyright information in PMC

References

    1. Durot E, Tomowiak C, Michallet AS, et al. . Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol. 2017;179(3):439-448. - PubMed
    1. Castillo JJ, Gustine J, Meid K, Dubeau T, Hunter ZR, Treon SP. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. Am J Hematol. 2016;91(10):1032-1035. - PubMed
    1. Zanwar S, Abeykoon JP, Durot E, et al. . Impact of MYD88L265P mutation status on histological transformation of Waldenström macroglobulinemia. Am J Hematol. 2020;95(3):274-281. - PubMed
    1. Durot E, Kanagaratnam L, Zanwar S, et al. . A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2021;106(11):2940-2946. - PMC - PubMed
    1. Boehme V, Zeynalova S, Kloess M, et al. . Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma study group (DSHNHL). Ann Oncol. 2007;18(1):149-157. - PubMed

Publication types